Krilogy Financial LLC Acquires 1,343 Shares of Pfizer Inc. (NYSE:PFE)

Krilogy Financial LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,191 shares of the biopharmaceutical company’s stock after purchasing an additional 1,343 shares during the quarter. Krilogy Financial LLC’s holdings in Pfizer were worth $699,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc bought a new stake in Pfizer during the 3rd quarter valued at approximately $30,000. GoalVest Advisory LLC increased its position in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $32,000. Trivant Custom Portfolio Group LLC lifted its stake in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. Finally, VisionPoint Advisory Group LLC lifted its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 3.0 %

Shares of Pfizer stock traded down $0.90 during midday trading on Thursday, hitting $28.70. The company’s stock had a trading volume of 41,998,922 shares, compared to its average volume of 42,563,102. The firm has a market capitalization of $162.63 billion, a P/E ratio of -478.25, a PEG ratio of 1.11 and a beta of 0.63. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The stock has a 50-day simple moving average of $27.24 and a 200-day simple moving average of $27.97.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period last year, the company earned $1.23 earnings per share. The business’s revenue was down 19.5% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.39 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 5.85%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Analysts Set New Price Targets

Several research firms have recently issued reports on PFE. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Morgan Stanley increased their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.